Table 3.
No | Author | Design | Threshold Gene | Age * | Clinical severity | Reported Treatment | Size | Sampling Location | 2 Consecutive negatives Day -1 | 2 Consecutive negatives Last positive | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | |||||||||
34 | Chen [42] | Retrospective | WHO | 51•0 | Mild | NS | 2 | Pharyngeal | 4•5 | 2•1 | 3•5 | 2•1 |
2 | Stool | 10•5 | 3•5 | 9•5 | 3•5 | |||||||
Moderate | 30 | Pharyngeal | 6•6 | 4•3 | 5•6 | 4•3 | ||||||
17 | Stool | 11•7 | 7•2 | 9•9 | 7•2 | |||||||
Severe | 10 | Pharyngeal | 13•4 | 3•2 | 10• | 3 | ||||||
9 | Stool | 8 | 4•9 | 14•2 | 6•1 | |||||||
35 | Lo [43] | Case series | Ct > 38 ORF1ab, N |
54•0 | Mild | L/R | 2 | Faeces | 16•5 | 0•7 | 15•0 | 1•4 |
2 | Nasopharyngeal | 13•0 | 5•7 | 12•0 | 7•1 | |||||||
Moderate-Severe | 7 | Faeces | 13•7 | 3•5 | 12•1 | 3•6 | ||||||
8 | Nasopharyngeal | 12•5 | 6•6 | 12•0 | 6•9 | |||||||
36 | Xing [44] | Case series | [45] | 5•0 | Mild | aIFN +Ribavirin | 3 | Faeces | 12•7 | 2•5 | ||
3 | Throat | 18•7 | 12•1 | |||||||||
37 | Xu [46] | Case series | Ct > 40 ORFab1, N |
51•0 | Mild | NS | 47 | Throat | 11•4 | 5•6 |
No recurrence was reported for these studies. Blank columns apply if sampling was daily (value of Day -1 equals last positive) or no recurrence occurred.
aIFN: Alpha interferon, Ct = Threshold cycle, L/R: Lopinavir/Ritonavir, N: Truncated nucleocapsid, ORF: Open reading frame, SD: Standard deviation, WHO: World health organization;
Age displayed as median in years